European Society for Medical Oncology (ESMO)

Results from the PAOLA/ENGOT-ov25 study indicate that adding olaparib to maintenance bevacizumab after first-line platinum-based chemotherapy for patients with newly diagnosed high-grade ovarian cancer improves second progression-free survival and time to second subsequent therapy or death. Read More ›

Platinum treatment after PARP inhibitor failure in patients with high-grade serous ovarian cancer was most effective in terms of objective response rate, progression-free survival, and overall survival when the platinum-free interval was >12 months Read More ›

Atezolizumab in combination with paclitaxel, carboplatin, and bevacizumab as first-line treatment for patients with newly diagnosed stage III or stage IV ovarian cancer did not improve progression-free survival or overall survival but exploratory subgroup analyses are ongoing. Read More ›

The final results of the FORWARD II phase 1b study investigating the efficacy, safety, and tolerability of mirvetuximab soravtansine in combination with carboplatin and bevacizumab in patients with recurrent platinum-sensitive ovarian cancer revealed an overall response rate of 83% and reasonable tolerability. Read More ›

Patient-reported outcomes from the PRIMA trial comparing niraparib treatment versus placebo for patients with newly diagnosed advanced ovarian, primary peritoneal, or fallopian tube cancer with a complete or partial response to first-line platinum-based chemotherapy were similar for the niraparib and placebo arms. Read More ›

Although the combination of 2 antivascular agents showed preliminary efficacy, increased cardiac toxicity has resulted in premature discontinuation of the trial. Read More ›

Patients receiving psychological support in the OVPSYCH2 randomized study showed reduced fear of progression compared with those without support. Read More ›

The novel combination of carboplatin, pegylated liposomal doxorubicin, and bevacizumab has a promising safety and efficacy profile. Read More ›

Promising safety results from the CORAIL trial suggest a place for lurbinectedin in treating platinum-resistant ovarian cancer. Read More ›

Progression-free survival associated with rucaparib is not affected by the number of prior chemotherapy regimens. Read More ›